Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic board backs higher bid amid shareholder holdout
16 Oct 2025, 05:28BAVA.CONASDAQ Copenhagen

Bavarian Nordic's board of directors on Thursday reiterated its recommendation for shareholders to accept a takeover offer from a private equity consortium led by Nordic Capital and Permira.

Private equity raises Bavarian Nordic bid, faces shareholder test
15 Oct 2025, 15:59BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has raised its takeover bid for Danish vaccine maker Bavarian Nordic to 250 Danish Krone per share from 233 Danish Krone.

Nordic Capital, Permira clear final hurdle for Bavarian Nordic takeover
9 Oct 2025, 12:24BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has received the final regulatory approval needed for its proposed takeover of Danish vaccine maker Bavarian Nordic.

Bavarian Nordic's mpox vaccine shows strong results in children
7 Oct 2025, 14:59BAVA.CONASDAQ Copenhagen

Bavarian Nordic said Tuesday its mpox and smallpox vaccine produced a strong immune response and was well-tolerated in children aged 2 to 11 in a clinical study.

Bavarian Nordic posts strong results ahead of PE buyout
22 Aug 2025, 05:38BAVA.CONASDAQ Copenhagen

Danish vaccine maker Bavarian Nordic on Friday reported a 33% rise in first-half revenue, posting strong results as it prepares for a takeover by a private equity consortium.

Bavarian Nordic agrees to DKK 19 billion takeover offer
6 Aug 2025, 20:30BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has agreed to acquire Danish vaccine maker Bavarian Nordic in an all-cash deal valuing the company at approximately 19 billion Danish Krone.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic A/S – Notice Convening Ordinary General Meeting 28 Mar 2019
Bavarian Nordic Awards Restricted Stock Units to Executive Management21 Mar 2019
Bavarian Nordic Announces Annual Report 201821 Mar 2019
Bavarian Nordic Announces FDA Delay in the Review of the Biologics License Application for MVA-BN Smallpox Vaccine11 Mar 2019
Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen21 Feb 2019
Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine18 Jan 2019
Bavarian Nordic A/S - Articles of Association7 Jan 2019
Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine21 Dec 2018
Bavarian Nordic - Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program13 Nov 2018
Bavarian Nordic Announces Interim Results for the First Nine Months of 20189 Nov 2018
Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers2 Nov 2018
Henrik Juuel Joins Bavarian Nordic as Chief Financial Officer1 Nov 2018
  • Previous
  • 1
  • More pages
  • 26
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 27
  • 28
  • More pages
  • 78
  • Next
  • Filings
    927